By inhibiting PDE4, apremilast increases the levels of cAMP in immune cells, leading to a reduction in the production of pro-inflammatory cytokines and an increase in the production of anti-inflammatory cytokines.
Apremilast was approved by the US FDA in 2014 and is marketed under the brand name Otezla. It is usually taken twice a day and is available in tablet form. Like any medication, apremilast can cause side effects, including nausea, diarrhea, headache, and upper respiratory tract infection. It is important to talk to your doctor before taking apremilast and to report any side effects you experience while taking the medication.
